Novogen and its subsidiaries Marshall Edwards, Inc., and Glycotex, Inc., (the Novogen Group) are involved in an active clinical research program of clinical trials with a number of drugs in different countries.  This program is detailed in the table appearing below. 

If you are a physician or a patient and simply want to now more about these trials then please send an e-mail to the following address: drugtrials@novogen.com

If you are seeking to join a study, then you should be aware that clinical studies of the Novogen Group's new drugs are conducted independently by highly respected hospitals and clinics.  That is, it is the doctors in those hospitals and clinics who plan and run the studies.  The Novogen Group sponsors the studies by funding them and by providing the drug, but is not involved in the running of the studies.  This independence is important in ensuring that the clinical studies are run in an objective and unbiased way.  The enrolment of patients into these studies is entirely under the control of the doctors in charge of the studies and the Novogen Group has no control or influence over this.  The Novogen Group is able to provide contact details of hospital clinical trials to patients and physicians seeking such information, but acceptance into those studies is entirely at the discretion of the particular hospital. 

The status of the Novogen Group's clinical trial program is as follows: